EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review

Cesario Bellantuono, Marianna Vargas, Gabriele Mandarelli, Bernardo Nardi, Maria Giulia Martini

Human Psychopharmacology: Clinical and Experimental · 2015-05 · 30 (3) · 143-151

DOI: 10.1002/hup.2473 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 18.03.2015. Verfasst von Cesario Bellantuono und 4 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Unit and DEGRA Center, United Hospitals of Ancona and Academic Department of Experimental and Clinical Medicine, Polytechnic University o…. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The present study provides a comprehensive review of the existing literature on the safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and lactation.

Methods

Studies published in English, reporting the use of SNRIs in pregnant and/or breastfeeding women, were identified by searching MEDLINE/Pubmed, PsycINFO, and EMBASE.

Results

Twenty‐nine studies were included in the review. Altogether, the initial evidence coming from the reviewed studies suggests a lack of association between SNRIs and an increased risk of major congenital malformations. Conversely, exposure to SNRIs seems to be significantly associated with an increased risk of some perinatal complications. No neonatal adverse events emerged, so far, in the few studies concerning the safety of SNRIs during breastfeeding.

Conclusions

Available data suggest that venlafaxine is relatively safe during pregnancy, in particular as far as major malformations are concerned, whereas considering the small number of studies published, no definitive conclusions can be drawn on its safety during breastfeeding. Because of the few studies so far published, the safety of duloxetine during pregnancy and breastfeeding remains to be well established. Copyright © 2015 John Wiley & Sons, Ltd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abnormalities, Drug-InducedBreast FeedingDuloxetine HydrochlorideFemaleHumansInfant, NewbornLactationPregnancyPregnancy ComplicationsSerotonin and Noradrenaline Reuptake InhibitorsVenlafaxine Hydrochloride

Stichwörter der Autor:innen

SNRIbreastfeedingmajor malformationsperinatal complicationspregnancy

Substanzen

Serotonin and Noradrenaline Reuptake InhibitorsVenlafaxine HydrochlorideDuloxetine Hydrochloride

Autor:innen und Institutionen

  • Psychiatric Unit and DEGRA Center, United Hospitals of Ancona and Academic Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.

Zitieren

APA

Bellantuono, C., Vargas, M., Mandarelli, G., Nardi, B., & Martini, M. G. (2015). The safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Human Psychopharmacology: Clinical and Experimental, 30(3), 143-151. https://doi.org/10.1002/hup.2473

Vancouver

Bellantuono C, Vargas M, Mandarelli G, Nardi B, Martini MG. The safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Human Psychopharmacology: Clinical and Experimental. 2015;30(3):143-151. doi:10.1002/hup.2473

BibTeX
@article{Bellantuono2015,
  author = {Bellantuono, Cesario and Vargas, Marianna and Mandarelli, Gabriele and Nardi, Bernardo and Martini, Maria Giulia},
  title = {The safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2015},
  volume = {30},
  number = {3},
  pages = {143--151},
  doi = {10.1002/hup.2473}
}
Kostenlos starten →